Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 12 of 12 publications.
Skip to main content
Khan S, Zimovetz E, Healey P, Copley-Merriman K. Biologics in ulcerative colitis (UC): treatment guidelines, health technology assessments (HTA). Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy. [abstract] Value Health. 2015 Nov; 18(7):A633.
Lebwohl M, Sherif B, Mollon P, Williams N, Fox T, Papavassilis C, Strober B, Gottlieb A. Secukinumab relieves pain and anxiety in psoriasis: results of two phase 3 trials. Poster presented at the 24th European Academy of Dermatology and Venereology Congress; October 2015. Copenhagen, Denmark.
Elewski B, Williams N, Mollon P, Sherif B, Fox T, Papavassilis C, Puig L. Psoriasis skin clearance is associated with patient-reported impact. Poster presented at the 24th European Academy of Dermatology and Venereology Congress; October 2015. Copenhagen, Denmark.
Strober B, Mordin M, Mollon, P, Williams N, Fox T, Papavassilis C, Lebwohl M. Secukinumab demonstrates greater impact on patient global impression of change than etanercept in moderate to severe psoriasis. Poster presented at the 24th European Academy of Dermatology and Venereology Congress; October 2015. Copenhagen, Denmark.
Chang J, Ngai C, Odom DM, Radder CN, Kappeler C, Xu R, Qin S, Kim T, Li J. Effects of regorafenib (REG) therapy on health-related quality of life (HRQoL) in patients with metastatic colorectal cancer (mCRC) in the phase III CONCUR trial. Poster presented at the 2015 ASCO Annual Meeting; May 29, 2015. Chicago, IL.
Chang J, Odom D, Radder C, Kappeler C, Xu R-h, Qin S, Kim TW, Li J. A post-hoc health-related quality of life analysis of patients with metastatic colorectal cancer in the phase III CONCUR trial. Poster presented at the ASCO Gastrointestinal Symposium 2015; May 2015. Chicago, IL. [abstract] J Clin Oncol. 2015 May; 33(Suppl 3):a667.
Spelman LJ, Lebwohl M, Mordin M, Mallya UG, Gnanasakthy A, Fox T. Secukinumab treatment provides fast relief from patient-reported psoriasis burden. Poster presented at the 48th Australasian College of Dermatologists Annual Scientific Meeting; May 2015. Adelaide, Australia. [abstract] Australas J Dermatol. 2015 May; 56(Suppl 2):73.
Foley P, Sherif B, Mallya UG, Fox T, Gottlieb AB. Secukinumab treatment sustains patient-reported outcome benefits through 1 year. Poster presented at the 48th Australasian College of Dermatologists Annual Scientific Meeting; May 2015. Adelaide, Australia. [abstract] Australas J Dermatol. 2015 May; 56(Suppl 2):56.
Collins A, Hawe E, Vickers A, Mallya UG, McBride D, Capkun-Niggli G, Olson M, Thorlund K. Secukinumab 300 mg demonstrates higher probability of efficacy than other biologics in psoriasis: indirect comparison. Poster presented at the 48th Australasian College of Dermatologists Annual Scientific Meeting; May 2015. Adelaide, Australia.
Sinclair R, McLeod L, Mallya UG, Fox T, Strober B. Psoriasis patients with PASI90 response achieve greater health-related quality of life improvements than those with PASI75 response. Poster presented at the 48th Australasian College of Dermatologists Annual Scientific Meeting; May 2015. Adelaide, Australia. [abstract] Australas J Dermatol. 2015 May; 56(S2):68.
Zhou X, Wang J, Zhang J, Copley-Merriman C, Torigoe Y, Reyes C, Seymour JF, Offner FC, Trneny M, Salles GA. Symptoms and toxicity of rituximab maintenance relative to observation following immunochemotherapy in patients with follicular lymphoma. Hematology. 2015 Apr;129(36). doi: 10.1179/1607845414Y.0000000179
Chang J, Odom DM, Radder CN, Kappeler C, Xu R, Qin S, Kim T, Li J. A post-hoc health-related quality of life (HRQoL) analysis of patients with metastatic colorectal cancer (mCRC) in the phase III CONCUR trial. Poster presented at the 2015 Gastrointestinal Cancers Symposium; January 15, 2015. San Francisco, CA.